Khan Rafay, Nai Qiang, Zhang Ping, Luo Hongxiu, Sen Shraman, Sidhom Ibrahim, Mathew Teena, Islam Mohammad, Sen Shuvendu, Yousif Abdalla
Department of Internal Medicine, Raritan Bay Medical Center, Perth Amboy, NJ 07733, USA.
Mol Clin Oncol. 2016 Jan;4(1):134-136. doi: 10.3892/mco.2015.667. Epub 2015 Oct 30.
Pancreatic cancer is one of the deadliest cancers commonly diagnosed at an advanced stage. Early diagnosis is crucial for the timely and potentially curative treatment of this highly fatal disease. Although screening tests have improved the survival rate in malignancies such as colon, breast, cervical and prostate cancer, there is currently no effective screening method available for the early detection of pancreatic cancer. As the sensitivity and specificity of existing biomarkers, such as carbohydrate antigen 19-9, for the early detection of pancreatic cancer is low, there is a pressing need for the identification of novel cancer markers. An increase in erythropoietin (EPO) levels has been observed in several cases of pancreatic neoplasms. However, the potential role of EPO as a biomarker of pancreatic cancer or malignant transformation requires further investigation. We herein present a case of increased EPO levels in an adult male patient with stage IV pancreatic cancer.
胰腺癌是最致命的癌症之一，通常在晚期才被诊断出来。早期诊断对于及时治疗这种高度致命的疾病并有可能治愈至关重要。尽管筛查测试提高了结肠癌、乳腺癌、宫颈癌和前列腺癌等恶性肿瘤的生存率，但目前尚无有效的筛查方法可用于早期检测胰腺癌。由于现有生物标志物（如糖类抗原19-9）对胰腺癌早期检测的敏感性和特异性较低，因此迫切需要鉴定新的癌症标志物。在几例胰腺肿瘤病例中观察到促红细胞生成素（EPO）水平升高。然而，EPO作为胰腺癌或恶性转化生物标志物的潜在作用需要进一步研究。我们在此报告一例IV期胰腺癌成年男性患者EPO水平升高的病例。
